DS 102

Drug Profile

DS 102

Alternative Names: 15-HEPE; 5-hydroxyeicosapentaenoic acid; AF-102 - Afimmune; DS102

Latest Information Update: 31 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DS Biopharma
  • Developer Afimmune; DS Biopharma
  • Class Antifibrotics; Lipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • Phase I Hepatic fibrosis

Most Recent Events

  • 18 Oct 2017 Afimmune receives patent allowance for DS 102 in USA
  • 29 Mar 2017 Afimmune plans a phase IIb trial for Non-alcoholic steatohepatitis (PO) (NCT03452540)
  • 27 Sep 2016 Phase-II clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (PO) (NCT03414541)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top